ADIL — Adial Pharmaceuticals Balance Sheet
0.000.00%
- $7.22m
- $2.62m
- 10
- 25
- 49
- 16
Annual balance sheet for Adial Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 4.4 | 6.06 | 4 | 2.83 | 3.75 |
| Prepaid Expenses | |||||
| Total Current Assets | 5.14 | 6.46 | 4.78 | 3.2 | 4.06 |
| Net Property, Plant And Equipment | — | 0.304 | 0.244 | — | — |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Total Assets | 5.49 | 7.47 | 5.73 | 4.74 | 5.04 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1.51 | 2.72 | 1.79 | 0.653 | 0.976 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 1.51 | 3.97 | 2.46 | 0.653 | 0.976 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 3.99 | 3.51 | 3.28 | 4.08 | 4.07 |
| Total Liabilities & Shareholders' Equity | 5.49 | 7.47 | 5.73 | 4.74 | 5.04 |
| Total Common Shares Outstanding |